After NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with comments that forced a delay to its final appraisal document.

But few treatment options exist. Pharmaceutical firms Amgen and Novartis are seeking to change that with Aimovig, which in May became the first Food and Drug Administration–approved drug ...